PortalPublikationenAllogeneic Stem Cell Transplantation for Myelodysplastic Syn...

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion

Standard

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion. / Garderet, Laurent; Ziagkos, Dimitris; van Biezen, Anja; Iacobelli, Simona; Finke, Jürgen; Maertens, Johan; Volin, Liisa; Ljungman, Per; Chevallier, Patrice; Passweg, Jakob; Schaap, Nicolaas; Beelen, Dietrich; Nagler, Arnon; Blaise, Didier; Poiré, Xavier; Yakoub-Agha, Ibrahim; Lenhoff, Stig; Craddock, Charles; Schots, Rik; Rambaldi, Alessandro; Sanz, Jaime; Jindra, Pavel; Mufti, Ghulam J; Robin, Marie; Kröger, Nicolaus.

in: BIOL BLOOD MARROW TR, Jahrgang 24, Nr. 3, 03.2018, S. 507-513.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Garderet, L, Ziagkos, D, van Biezen, A, Iacobelli, S, Finke, J, Maertens, J, Volin, L, Ljungman, P, Chevallier, P, Passweg, J, Schaap, N, Beelen, D, Nagler, A, Blaise, D, Poiré, X, Yakoub-Agha, I, Lenhoff, S, Craddock, C, Schots, R, Rambaldi, A, Sanz, J, Jindra, P, Mufti, GJ, Robin, M & Kröger, N 2018, 'Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion', BIOL BLOOD MARROW TR, Jg. 24, Nr. 3, S. 507-513. https://doi.org/10.1016/j.bbmt.2017.11.017

APA

Garderet, L., Ziagkos, D., van Biezen, A., Iacobelli, S., Finke, J., Maertens, J., Volin, L., Ljungman, P., Chevallier, P., Passweg, J., Schaap, N., Beelen, D., Nagler, A., Blaise, D., Poiré, X., Yakoub-Agha, I., Lenhoff, S., Craddock, C., Schots, R., ... Kröger, N. (2018). Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion. BIOL BLOOD MARROW TR, 24(3), 507-513. https://doi.org/10.1016/j.bbmt.2017.11.017

Vancouver

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J et al. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion. BIOL BLOOD MARROW TR. 2018 Mär;24(3):507-513. https://doi.org/10.1016/j.bbmt.2017.11.017

Bibtex

@article{9a7930d61b84440ca6c621bbb12705de,
title = "Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion",
abstract = "The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.",
keywords = "Journal Article",
author = "Laurent Garderet and Dimitris Ziagkos and {van Biezen}, Anja and Simona Iacobelli and J{\"u}rgen Finke and Johan Maertens and Liisa Volin and Per Ljungman and Patrice Chevallier and Jakob Passweg and Nicolaas Schaap and Dietrich Beelen and Arnon Nagler and Didier Blaise and Xavier Poir{\'e} and Ibrahim Yakoub-Agha and Stig Lenhoff and Charles Craddock and Rik Schots and Alessandro Rambaldi and Jaime Sanz and Pavel Jindra and Mufti, {Ghulam J} and Marie Robin and Nicolaus Kr{\"o}ger",
note = "Copyright {\textcopyright} 2017. Published by Elsevier Inc.",
year = "2018",
month = mar,
doi = "10.1016/j.bbmt.2017.11.017",
language = "English",
volume = "24",
pages = "507--513",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion

AU - Garderet, Laurent

AU - Ziagkos, Dimitris

AU - van Biezen, Anja

AU - Iacobelli, Simona

AU - Finke, Jürgen

AU - Maertens, Johan

AU - Volin, Liisa

AU - Ljungman, Per

AU - Chevallier, Patrice

AU - Passweg, Jakob

AU - Schaap, Nicolaas

AU - Beelen, Dietrich

AU - Nagler, Arnon

AU - Blaise, Didier

AU - Poiré, Xavier

AU - Yakoub-Agha, Ibrahim

AU - Lenhoff, Stig

AU - Craddock, Charles

AU - Schots, Rik

AU - Rambaldi, Alessandro

AU - Sanz, Jaime

AU - Jindra, Pavel

AU - Mufti, Ghulam J

AU - Robin, Marie

AU - Kröger, Nicolaus

N1 - Copyright © 2017. Published by Elsevier Inc.

PY - 2018/3

Y1 - 2018/3

N2 - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

AB - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

KW - Journal Article

U2 - 10.1016/j.bbmt.2017.11.017

DO - 10.1016/j.bbmt.2017.11.017

M3 - SCORING: Journal article

C2 - 29196078

VL - 24

SP - 507

EP - 513

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 3

ER -